See more : Aimrite Holdings Corporation (AIMH) Income Statement Analysis – Financial Results
Complete financial analysis of ZyVersa Therapeutics, Inc. (ZVSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZyVersa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mission Advancement Corp. (MACC-UN) Income Statement Analysis – Financial Results
- Okamura Corporation (OKAMF) Income Statement Analysis – Financial Results
- Business Alignment Public Company Limited (BIZ.BK) Income Statement Analysis – Financial Results
- Prospex Energy PLC (PXEN.L) Income Statement Analysis – Financial Results
- KR1 Plc (KROEF) Income Statement Analysis – Financial Results
ZyVersa Therapeutics, Inc. (ZVSA)
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 10.40K | 10.40K | 10.40K | 10.40K |
| Gross Profit | -10.40K | -10.40K | -10.40K | -10.40K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.21M | 5.41M | 2.12M | 6.47M |
| General & Administrative | 11.21B | 7.61M | 5.58M | 5.36M |
| Selling & Marketing | -11.20B | 0.00 | 0.00 | 0.00 |
| SG&A | 11.20M | 7.61M | 5.58M | 5.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 13.01M | 7.70M | 11.83M |
| Cost & Expenses | 14.42M | 13.01M | 7.70M | 11.83M |
| Interest Income | 0.00 | 427.54 | 821.37 | 516.45 |
| Interest Expense | -457.00K | 427.54K | 821.37K | 516.45K |
| Depreciation & Amortization | 10.40K | 10.40K | 10.40K | 10.40K |
| EBITDA | -107.74M | -11.67M | -7.25M | -12.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -14.42M | -13.01M | -7.70M | -11.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -93.33M | -2.37M | -379.79K | -850.11K |
| Income Before Tax | -107.75M | -14.05M | -8.08M | -12.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.46M | 745.05M | 821.37K | 516.45K |
| Net Income | -98.30M | -759.10M | -8.91M | -13.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.09K | -930.25 | -173.66 | -272.45 |
| EPS Diluted | -1.09K | -930.25 | -173.66 | -272.45 |
| Weighted Avg Shares Out | 97.50K | 25.95K | 46.55K | 46.55K |
| Weighted Avg Shares Out (Dil) | 97.50K | 25.95K | 46.55K | 46.55K |
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100's Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
Atherosclerosis, an inflammatory disease characterized by buildup of cholesterol, lipids, and other substances (plaque) in arteries leading to heart attack and stroke, is accelerated in patients with diabetes. The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation...
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
WESTON, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or the “Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet needs, announces that...
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD). Granted a European patent covering use of VAR 200 (2-hydroxypropyl-beta-cyclodextrin) in diabetic nephropathy/diabetic kidney disease.
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract affecting 1 in 100 Americans (around 2.4 million people) that can lead to disabling bowel symptoms and progressive bowel damage. Study provides direct evidence that NLRP3 signaling...
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
Despite decades of effective environmental policy and improved air quality in the US, air pollution remains the greatest environmental health risk factor, contributing to 100,000 to 200,000 incremental deaths annually, primarily from fine particulate matter (PM 2.5 ) derived from...
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection
NLRP3 Inflammasome Inhibition Alleviates Neurological Impairment in the Brain of MS Mouse Model, Reinforcing Published Data for IC 100 in MS Mouse Model.
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
Paper reports that obesity exacerbates scarring of the heart's muscular tissue (myocardial fibrosis) through recruitment of inflammasome ASC to the heart's mitochondria, facilitating NLRP3 inflammasome assembly and activation leading to damaging inflammation Obesity, which affects over 650 million adults, is...
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
Chronic kidney disease is most common in people 65 years and older. NLRP3 inflammasomes signaling in the kidneys' filtration system (“glomerular podocytes”) occurs as early as middle age, leading to scarring, podocyte loss, and impaired function, which may be a...
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200's Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
Cholesterol accumulation in the kidneys' podocytes from impaired efflux out of cells is one of the hallmarks of kidney injury in chronic kidney disease.
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
Brain inflammation from traumatic injury releases proinflammatory cytokines that activate inflammasomes in the heart leading to damaging inflammation.
Source: https://incomestatements.info
Category: Stock Reports
What were ZyVersa’s Q3 2024 net losses?
Net losses were approximately $2.4 million for the three months ended September 30, 2024, with an improvement of approximately $0.5 million or 17.3% compared to a net loss of approximately $2.9 million for the three months ended September 30, 2023.